REGENXBIO, which is developing gene therapies for rare diseases with a proprietary delivery platform, raised the proposed deal size for its upcoming IPO on Wednesday. The Rockville, MD-based company now plans to raise $122 million by offering 5.6 million shares at $22 per share. The company had previously filed to offer the same number of shares at a range of $17 to $19. At $22 per share, REGENXBIO would raise 22% greater proceeds than previously anticipated.
Help employers find you! Check out all the jobs and post your resume.
